Pharmaceuticals in Sweden
Published: November 2012 · Publisher: MarketLine
Pharmaceuticals in Sweden industry profile provides top-line qualitative and quantitative summary information including: market size (value 2007-11, and forecast to 2016).
- Description
- Table of Contents
- Ask a Question
Introduction
Pharmaceuticals in Sweden industry profile provides top-line qualitative and quantitative summary information including: market size (value 2007-11, and forecast to 2016). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Sweden pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
Highlights
*The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare.
*The Swedish pharmaceuticals market had total revenues of $4.7 billion in 2011, representing a compound annual growth rate (CAGR) of 2.2% between 2007 and 2011.
*0
*The performance of the market is forecast to decelerate, with an anticipated CAGR of 1.4% for the five-year period 2011 - 2016, which is expected to drive the market to a value of $5.1 billion by the end of 2016.
Features
Save time carrying out entry-level research by identifying the size, growth, and leading players in the pharmaceuticals market in Sweden
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in Sweden
Leading company profiles reveal details of key pharmaceuticals market players’ global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the Sweden pharmaceuticals market with five year forecasts
Macroeconomic indicators provide insight into general trends within the Sweden economy
Key Questions Answered
What was the size of the Sweden pharmaceuticals market by value in 2011?
What will be the size of the Sweden pharmaceuticals market in 2016?
What factors are affecting the strength of competition in the Sweden pharmaceuticals market?
How has the market performed over the last five years?
Pharmaceuticals in Sweden industry profile provides top-line qualitative and quantitative summary information including: market size (value 2007-11, and forecast to 2016). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Sweden pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
Highlights
*The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare.
*The Swedish pharmaceuticals market had total revenues of $4.7 billion in 2011, representing a compound annual growth rate (CAGR) of 2.2% between 2007 and 2011.
*0
*The performance of the market is forecast to decelerate, with an anticipated CAGR of 1.4% for the five-year period 2011 - 2016, which is expected to drive the market to a value of $5.1 billion by the end of 2016.
Features
Save time carrying out entry-level research by identifying the size, growth, and leading players in the pharmaceuticals market in Sweden
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in Sweden
Leading company profiles reveal details of key pharmaceuticals market players’ global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the Sweden pharmaceuticals market with five year forecasts
Macroeconomic indicators provide insight into general trends within the Sweden economy
Key Questions Answered
What was the size of the Sweden pharmaceuticals market by value in 2011?
What will be the size of the Sweden pharmaceuticals market in 2016?
What factors are affecting the strength of competition in the Sweden pharmaceuticals market?
How has the market performed over the last five years?
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.
TABLE OF CONTENTS
Executive Summary 2
Market value 2
Market value forecast 2
Geography segmentation 2
Market share 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 8
Market value 8
Market Segmentation 9
Geography segmentation 9
Market share 10
Market Outlook 11
Market value forecast 11
Five Forces Analysis 12
Summary 12
Buyer power 13
Supplier power 15
New entrants 16
Threat of substitutes 18
Degree of rivalry 19
Leading Companies 20
Johnson & Johnson 20
Pfizer Inc. 23
AstraZeneca PLC 26
Novartis AG 30
Macroeconomic Indicators 33
Country Data 33
Appendix 35
Methodology 35
Industry associations 36
Related research 36
LIST OF TABLES
Table 1: Sweden pharmaceuticals market value: $ billion, 2007–11 8
Table 2: Sweden pharmaceuticals market geography segmentation: $ billion, 2011 9
Table 3: Sweden pharmaceuticals market share: % share, by value, 2011 10
Table 4: Sweden pharmaceuticals market value forecast: $ billion, 2011–16 11
Table 5: Johnson & Johnson: key facts 20
Table 6: Johnson & Johnson: key financials ($) 21
Table 7: Johnson & Johnson: key financial ratios 21
Table 8: Pfizer Inc.: key facts 23
Table 9: Pfizer Inc.: key financials ($) 24
Table 10: Pfizer Inc.: key financial ratios 24
Table 11: AstraZeneca PLC: key facts 26
Table 12: AstraZeneca PLC: key financials ($) 27
Table 13: AstraZeneca PLC: key financial ratios 28
Table 14: Novartis AG: key facts 30
Table 15: Novartis AG: key financials ($) 31
Table 16: Novartis AG: key financial ratios 31
Table 17: Sweden size of population (million), 2007–11 33
Table 18: Sweden gdp (constant 2000 prices, $ billion), 2007–11 33
Table 19: Sweden gdp (current prices, $ billion), 2007–11 33
Table 20: Sweden inflation, 2007–11 34
Table 21: Sweden consumer price index (absolute), 2007–11 34
Table 22: Sweden exchange rate, 2007–11 34
LIST OF FIGURES
Figure 1: Sweden pharmaceuticals market value: $ billion, 2007–11 8
Figure 2: Sweden pharmaceuticals market geography segmentation: % share, by value, 2011 9
Figure 3: Sweden pharmaceuticals market share: % share, by value, 2011 10
Figure 4: Sweden pharmaceuticals market value forecast: $ billion, 2011–16 11
Figure 5: Forces driving competition in the pharmaceuticals market in Sweden, 2011 12
Figure 6: Drivers of buyer power in the pharmaceuticals market in Sweden, 2011 13
Figure 7: Drivers of supplier power in the pharmaceuticals market in Sweden, 2011 15
Figure 8: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Sweden, 2011 16
Figure 9: Factors influencing the threat of substitutes in the pharmaceuticals market in Sweden, 2011 18
Figure 10: Drivers of degree of rivalry in the pharmaceuticals market in Sweden, 2011 19
Figure 11: Johnson & Johnson: revenues & profitability 21
Figure 12: Johnson & Johnson: assets & liabilities 22
Figure 13: Pfizer Inc.: revenues & profitability 25
Figure 14: Pfizer Inc.: assets & liabilities 25
Figure 15: AstraZeneca PLC: revenues & profitability 28
Figure 16: AstraZeneca PLC: assets & liabilities 29
Figure 17: Novartis AG: revenues & profitability 32
Figure 18: Novartis AG: assets & liabilities 32
Executive Summary 2
Market value 2
Market value forecast 2
Geography segmentation 2
Market share 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 8
Market value 8
Market Segmentation 9
Geography segmentation 9
Market share 10
Market Outlook 11
Market value forecast 11
Five Forces Analysis 12
Summary 12
Buyer power 13
Supplier power 15
New entrants 16
Threat of substitutes 18
Degree of rivalry 19
Leading Companies 20
Johnson & Johnson 20
Pfizer Inc. 23
AstraZeneca PLC 26
Novartis AG 30
Macroeconomic Indicators 33
Country Data 33
Appendix 35
Methodology 35
Industry associations 36
Related research 36
LIST OF TABLES
Table 1: Sweden pharmaceuticals market value: $ billion, 2007–11 8
Table 2: Sweden pharmaceuticals market geography segmentation: $ billion, 2011 9
Table 3: Sweden pharmaceuticals market share: % share, by value, 2011 10
Table 4: Sweden pharmaceuticals market value forecast: $ billion, 2011–16 11
Table 5: Johnson & Johnson: key facts 20
Table 6: Johnson & Johnson: key financials ($) 21
Table 7: Johnson & Johnson: key financial ratios 21
Table 8: Pfizer Inc.: key facts 23
Table 9: Pfizer Inc.: key financials ($) 24
Table 10: Pfizer Inc.: key financial ratios 24
Table 11: AstraZeneca PLC: key facts 26
Table 12: AstraZeneca PLC: key financials ($) 27
Table 13: AstraZeneca PLC: key financial ratios 28
Table 14: Novartis AG: key facts 30
Table 15: Novartis AG: key financials ($) 31
Table 16: Novartis AG: key financial ratios 31
Table 17: Sweden size of population (million), 2007–11 33
Table 18: Sweden gdp (constant 2000 prices, $ billion), 2007–11 33
Table 19: Sweden gdp (current prices, $ billion), 2007–11 33
Table 20: Sweden inflation, 2007–11 34
Table 21: Sweden consumer price index (absolute), 2007–11 34
Table 22: Sweden exchange rate, 2007–11 34
LIST OF FIGURES
Figure 1: Sweden pharmaceuticals market value: $ billion, 2007–11 8
Figure 2: Sweden pharmaceuticals market geography segmentation: % share, by value, 2011 9
Figure 3: Sweden pharmaceuticals market share: % share, by value, 2011 10
Figure 4: Sweden pharmaceuticals market value forecast: $ billion, 2011–16 11
Figure 5: Forces driving competition in the pharmaceuticals market in Sweden, 2011 12
Figure 6: Drivers of buyer power in the pharmaceuticals market in Sweden, 2011 13
Figure 7: Drivers of supplier power in the pharmaceuticals market in Sweden, 2011 15
Figure 8: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Sweden, 2011 16
Figure 9: Factors influencing the threat of substitutes in the pharmaceuticals market in Sweden, 2011 18
Figure 10: Drivers of degree of rivalry in the pharmaceuticals market in Sweden, 2011 19
Figure 11: Johnson & Johnson: revenues & profitability 21
Figure 12: Johnson & Johnson: assets & liabilities 22
Figure 13: Pfizer Inc.: revenues & profitability 25
Figure 14: Pfizer Inc.: assets & liabilities 25
Figure 15: AstraZeneca PLC: revenues & profitability 28
Figure 16: AstraZeneca PLC: assets & liabilities 29
Figure 17: Novartis AG: revenues & profitability 32
Figure 18: Novartis AG: assets & liabilities 32
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.